Article

Expression of human chorionic gonadotropin beta-subunit type I genes predicts adverse outcome in renal cell carcinoma.

Helsinki University Central Hospital/Biomedicum Helsinki, Room A418a, Haartmaninkatu 8, P.O.B. 700, FIN-00029.
Journal of Molecular Diagnostics (impact factor: 3.58). 11/2006; 8(5):598-603. pp.598-603
Source: PubMed

ABSTRACT Expression of the free beta-subunit of human chorionic gonadotropin (hCGbeta) in malignant tumors is frequently associated with aggressive disease. The pretreatment serum concentration of hCGbeta is an independent prognostic variable in renal cell carcinoma (RCC). The three so-called type II genes (hCGbeta 3/9, 5, and 8) have been shown to be up-regulated in relation to type I genes (hCGbeta 6/7) in some malignant tumors. We developed a reverse transcription-polymerase chain reaction method for quantification of relative levels of the mRNAs for the two types of hCGbeta genes and studied the association between the expression in RCC tissue (n = 104) and clinical outcome. hCGbeta mRNA expression was detected in 40% (42 of 104) of the tumors, and in 40 of these (93%), this consisted of hCGbeta type I mRNA only, whereas type II hCGbeta mRNA was detected in two samples. hCGbeta mRNA expression was significantly associated with a shorter disease-specific (log-rank P = 0.023; median survival 1.4 versus 7.9 years) and overall survival (log-rank P = 0.011). In a Cox regression model, stage (P < 0.0001) and hCGbeta mRNA expression (P < 0.0001) were independent prognostic variables. We conclude that expression of type I hCGbeta genes indicates adverse prognosis in RCC.

0 0
 · 
0 Bookmarks
 · 
23 Views
  • Article: The Heidelberg classification of renal cell tumours.
    G Kovacs, M Akhtar, B J Beckwith, P Bugert, C S Cooper, B Delahunt, J N Eble, S Fleming, B Ljungberg, L J Medeiros, H Moch, V E Reuter, E Ritz, G Roos, D Schmidt, J R Srigley, S Störkel, E van den Berg, B Zbar
    [show abstract] [hide abstract]
    ABSTRACT: This paper presents the conclusions of a workshop entitled 'Impact of Molecular Genetics on the Classification of Renal Cell Tumours', which was held in Heidelberg in October 1996. The focus on 'renal cell tumours' excludes any discussion of Wilms' tumour and its variants, or of tumours metastatic to the kidneys. The proposed classification subdivides renal cell tumours into benign and malignant parenchymal neoplasms and, where possible, limits each subcategory to the most commonly documented genetic abnormalities. Benign tumours are subclassified into metanephric adenoma and adenofibroma, papillary renal cell adenoma, and renal oncocytoma. Malignant tumours are subclassified into common or conventional renal cell carcinoma; papillary renal cell carcinoma; chromophobe renal cell carcinoma; collecting duct carcinoma, with medullary carcinoma of the kidney; and renal cell carcinoma, unclassified. This classification is based on current genetic knowledge, correlates with recognizable histological findings, and is applicable to routine diagnostic practice.
    The Journal of Pathology 11/1997; 183(2):131-3. · 6.32 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

adverse prognosis
 
aggressive disease
 
clinical outcome
 
free beta-subunit
 
hCGbeta genes
 
hCGbeta mRNA expression
 
hCGbeta type
 
human chorionic gonadotropin
 
independent prognostic variable
 
log-rank P
 
malignant tumors
 
mRNAs
 
pretreatment serum concentration
 
relative levels
 
renal cell carcinoma
 
reverse transcription-polymerase chain reaction method
 
shorter disease-specific
 
three so-called type II genes
 
two types
 
type II hCGbeta mRNA